Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
The following is a summary of the Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript:
以下是Aptose Biosciences Inc.（APTO）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
In 2023, Aptose Biosciences managed to finance its activities through various sources, such as an ATM facility and a strategic investment by Hanmi Pharmaceutical.
The company closed financings with gross proceeds of $13.7 million in January.
The company ended the year with approximately $9.3 million, with a decrease in cash and investments of $27.7 million compared to December 2022.
The company recorded a net loss of about $51.2 million in 2023, translating into a $7.58 loss per share.
Having completed a financing campaign in January 2024, raising around $13.7 million, it is anticipated that the current resources will fund operations through August 2024.
Aptose raised $7.3 million through financing activities during 2023.
2023年，Aptose Biosciences設法通過各種來源爲其活動提供資金，例如自動櫃員機設施和韓美製藥的戰略投資。
該公司在1月份完成了融資，總收益爲1,370萬美元。
該公司在年底的收入約爲930萬美元，與2022年12月相比，現金和投資減少了2770萬美元。
該公司在2023年錄得約5,120萬美元的淨虧損，相當於每股虧損7.58美元。
在2024年1月完成融資活動後，籌集了約1,370萬美元，預計目前的資源將爲2024年8月之前的運營提供資金。
Aptose 在 2023 年通過融資活動籌集了 730 萬美元。
Business Progress:
業務進展：
Aptose's lead agent Tuspetinib, demonstrated powerful anti-leukemic activity and an excellent safety profile. The company plans to prioritize resources towards the TUS/VEN/HMA triplet study for frontline treatment of newly diagnosed AML patients.
Luxeptinib, another Aptose drug has completed patient enrollment and dosing in trials for B-cell malignancy and AML. A new G3 formulation with improved absorption and beter tolerance will be used for future studies.
The company is in ongoing discussions for potential partnerships for the development of tuspetinib. The launch of TUS/VEN/HMA registrational programs is expected in 2025.
Data presentation on single agent and doublet in relapsed/refractory patients at the EHA Conference is expected in June 2024.
The company has 15,706,810 common shares outstanding and 8,332,163 warrants at the end of 2023.
Aptose的主要藥物Tuspetinib表現出強大的抗白血病活性和出色的安全性。該公司計劃將資源優先用於TUS/VEN/HMA三聯研究，該研究旨在對新診斷的急性髓細胞白血病患者進行一線治療。
另一種Aptose藥物Luxeptinib已經完成了B細胞惡性腫瘤和急性髓細胞白血病試驗的患者入組和給藥。一種具有更好吸收和更好耐受性的新 G3 配方將用於未來的研究。
該公司正在討論開發tuspetinib的潛在合作伙伴關係。TUS/VEN/HMA註冊計劃預計將於2025年啓動。
預計將於2024年6月在EHA會議上公佈有關復發/難治性患者的單一藥物和雙聯藥物的數據。
截至2023年底，該公司有15,706,810股已發行普通股和8,332,163份認股權證。
More details: Aptose Biosciences IR
更多詳情： Aptose 生物科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。